Charles Town, WV – November 23, 2011 - ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) today announced plans to begin recruitment of physicians and subjects for clinical trials of its nutritional supplement, ReStore.
The ReStore formula, an all-natural, sugar-free gluten free energy supplement, under license, has been successfully used in the treatment and elimination of sub-clinical depression. One of its unique and unexpected beneficial effects is a marked increase in energy. ReBuilder Medical Technologies, Inc. is marketing ReStore as a nutritional supplement and energy drink that’s both safe and beneficial for diabetics and those suffering from the depressive effects of chronic pain, particularly the symptoms of diabetic peripheral neuropathy.
“Diabetics often suffer from vitamin B deficiencies, especially Vitamin B12,” said David B. Phillips, Ph.D., CEO of ReBuilder Medical Technologies, Inc. “ReStore has a full complement of B vitamins to support the health of diabetic’s nerve cells, and this results in better communication between the brain and the voluntary muscles. By increasing the efficiency of these connections, the patient receives more accurate feedback from his extremities and an increase in muscle fiber recruitment, so that it takes less expenditure of energy to move. All this translates into better mood and more energy.”
ReBuilder Medical Technologies, Inc. is best known as a leader in the treatment of diabetic peripheral neuropathy, a devastating condition caused by loss of blood flow to nerve tissue. In addition to causing pain and numbness in the feet and hands, peripheral neuropathy can lead to complete loss of mobility, gangrene, and eventual amputations. In addition, the company has had a strong series of market successes recently, including rapidly advancing sales and the development of several new market segments.
Based on proprietary market research estimates, Phillips estimates that 6 percent of this market is available to manufacturers of dietary supplements that hold promise of answering the average diabetic's grossly inconsistent energy levels and resultant depressive episodes. On average, patients spend $833 annually on attempts to normalize mood and energy. This translates into approximately $8 billion in sales per year. Capturing just 1 percent of this market could result in over $8,000,000 in sales for the company. The retail price of the product is $40 for a full month’s supply.
You can purchase ReStore online at www.rebuildermedical.com/products.
Dr. Wayne Chickowitz, N.D, president of the American College of Physical Medicine in Chicago, Il., will spearhead the planned clinical trials. “We have thousands of alumni available to test this product’s new application and could get initial results back in little as 90 days,” says Dr. Chickowitz.
About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc. is a manufacturer of emerging medical devices and innovative technologies founded by world-renowned medical device inventor David B. Phillips, Ph.D. ReBuilder Medical’s flagship product is its FDA registered ReBuilder System, used for treating peripheral neuropathy. Unlike current therapies for neuropathy (nerve disease) that depend on prescription drugs with powerful side effects, the ReBuilder System is a portable, battery-powered medical product that provides a unique, non-surgical treatment which is non-invasive, has no side effects and can actually strengthen muscles while increasing blood flow.
ReBuilder Medical Technologies, Inc. is located in Charles Town, WV. It’s CEO, David B. Phillips, Ph.D. is best known for inventing the very first infrared ear thermometer. Dr. Phillips also was responsible for the GST System, which is used for the early detection of breast cancer, and the AcuPen, a hand-held device that provides the benefits of acupuncture without the use of needles. The company is also involved in research and development on a number of other innovative products.
More information on ReBuilder Medical Technologies, Inc. and its products can be found at: www.rebuildermedical.com.
Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.